Key Takeaways
- Base business margin hit 38% despite a 12% revenue drop: US revenue stagnated because falling material costs pulled transfer prices lower, but margins held and new launches contributed at a 72% gross margin.
- Cenexi is still loss-making but the path to breakeven is now concrete: Q3 FY26 is the stated target, with double-digit EBITDA margin the year after, supported by a deliberate mix shift toward pre-filled syringes, lyophilized products and ophthalmic gels.
- GLP-1 entry is real and capacity is being built to capture it: Liraglutide launched, two contracts secured, and cartridge capacity is scaling from 4 crore to 14 crore units by end of this year, making Gland one of the top-tier cartridge players.
- The biologics/CDMO pivot is taking shape via partnerships, not just filings: A 15-product co-development deal, a Dr. Reddy's biologics collaboration (₹100 crore revenue in FY26), and a Henlius biosimilar CDMO agreement signal a shift toward complex modalities.
- What to watch next quarter: Whether Cenexi's Q3 FY26 breakeven stays on track as remediation and equipment issues at Fontenay resolve, the pace of new US launch commercialization against the 18% growth target, and any tariff pass-through friction that contradicts management's confidence.
Cenexi Turnaround: The Quarter's Central Problem
- Fontenay disruption was the main drag: Production fell because of ongoing remediation from the Q3 ANSM inspection plus two equipment breakdowns in the first two months of the quarter, cutting shipments and sales.
- Herouville remains below breakeven: Suboptimal utilization keeps the site loss-making, though several tech transfer projects in development are expected to eventually contribute to growth.
- Braine-l'Alleud met its target: The facility performed to plan, and two new lyophilizers arrived on site with qualification expected by end of calendar year 2025.
- The mix shift is the margin thesis: Management is deliberately moving away from low-value high-volume business (70% of current operations) toward pre-filled syringes, lyophilized products, and ophthalmic gels to expand net realizable value per unit.
- Operating leverage is built in: Injectable capacity overhead is roughly 80% fixed, and the current workforce is sufficient to handle additional lines without new hiring, so incremental volume should drop through at a high rate.
- Cross-selling remains an untapped lever: The strategic overlap between Cenexi's technology (oncology syringes, hormones, vaccines, biologics) and Gland's portfolio has not yet been pursued aggressively, with management waiting until current operations are on track.
Srinivas Sadu: "We recognize that the acquisition thesis has taken longer than expected to fructify, but our strategy to achieve robust growth and profitability remains centered on high value products."
US Business: Volume Up, Revenue Flat, Margins Protected
- Volume grew 9% for the full year but pricing declined 5%: The revenue stagnation happened because material costs fell for several key products, end-market prices adjusted downward, and transfer prices followed, leaving the top line flat while margins stayed intact.
- New launches are high-margin but still small: New products contributed 6% of overall US revenue in FY25 at a 72% gross margin versus the company average of 58%, and Q4 grew 10% sequentially over Q3.
- The top 10 molecules grew 26%: This signals that the core portfolio is being preserved even as pricing resets, with volume increases offsetting price declines.
- The FY26 growth target is 18%: Management expects 12% from products and 6% from CMO projects to the US, supported by continued momentum of roughly 33 new product launches.
- Tariff risk is acknowledged but dismissed: Management says tariffs apply to the transfer price, not the end price, so the impact is limited, and partners have shown no real concern with a clear understanding that any levy will be passed on.
Srinivas Sadu: "What happened also was the product, there were several key products where the material costs have gone down and the end market price also was reduced, the transfer price. So, the revenue came down, but the margin was intact."
GLP-1 & Complex Injectables: The Growth Bet
- Liraglutide launch marks entry into GLP-1: Two GLP-1 contracts are already secured, and the company is preserving capacity to allocate to the best partner for sustained business.
- Cartridge capacity is tripling: From 4 crore units currently to 14 crore by end of this year via a new 10-crore pen line costing roughly ₹120 crore, positioning Gland as one of the top-tier cartridge capacity companies in the country.
- Fill-and-finish pricing is in the $1–$2 range: Management disclosed this range while noting that annual repricing clauses with tier pricing based on volumes are standard in these contracts.
- Three more complex injectable approvals are anticipated: These sit alongside the 15-product co-development partnership (six 505(b)(2) and nine ANDA submissions) with a specialty injectable developer.
- Biologics revenue begins in FY26: The Dr. Reddy's collaboration is expected to contribute roughly ₹100 crore, gradually increasing thereafter, while the non-binding Henlius CDMO agreement positions Gland as a secondary manufacturing site for biosimilars.
ROW & Other Markets: A Reset Year
- ROW revenue fell 14% to ₹240.4 crore: The decline came from tender misses and softer order intake in key regions, though some capacity had also been diverted to the US and is now back on track.
- Management believes the business can double in 3–5 years: The strategy involves defining a non-Enoxaparin and non-heparin portfolio, with Saudi NUPCO tech transfer for Enoxaparin already underway with a local partner.
- India market growth is on the agenda: The plan is to leverage therapeutic area strengths and explore inorganic opportunities to achieve significant scale, though no specific timeline was given.
- The front-end US presence is paused, not abandoned: Evaluation continues but the tariff situation has put the initiative on hold, with management saying it is not off the table.
Shyamakant Giri: "We internally have reasons to believe that this business can double over the next 3 to 5 years."
Margins & Capital Allocation
- Base business EBITDA margin expanded to 38% from 36%: The improvement came from favorable product mix and cost optimization benefits, and management expects to maintain this 37–38% level going forward.
- Consolidated gross margin jumped to 66% from 61% YoY: Higher contribution from new launches and better raw material costs in key products drove the expansion.
- Cenexi employee costs run at 60–65% of revenue: Average manpower cost in Europe is around 40, comparatively higher than India, making the fixed-cost operating leverage story critical to the margin turnaround.
- Cenexi gross margin improved to 79% from 77% sequentially: The improvement came despite the Fontenay disruption, suggesting the mix shift is already helping at the gross level.
- Growth capex is flowing to capacity, not maintenance: In India, spending is focused on a new bag line and packing capacity; at Cenexi, a new PFS line (operational early CY2026), two lyophilizers, and additional vial/lyo capacity in Belgium over the next two years.
- Inorganic opportunities are being actively explored: The focus is on accelerating complex product development, accessing new technologies, expanding the product range, and entering new markets.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | Mid-teens growth | FY26 |
| Subsequent years growth | Low-20s growth | FY27–FY28 |
| US revenue growth | 18% (12% products, 6% CMO) | FY26 |
| Base business EBITDA margin | Maintain 37–38% | Ongoing |
| Cenexi breakeven | Positive EBITDA | Q3 FY26 |
| Cenexi EBITDA margin | Double-digit | FY27 |
| Cenexi revenue (with additional capex) | €30 crore | 3 years |
| Cenexi EBITDA margin (at €30 crore revenue) | High teens percentage | 3 years |
| Cartridge capacity | 14 crore units (new 10-crore line installed) | End of CY2025 |
| New PFS line (Cenexi) | Operational | Beginning of CY2026 |
| Lyophilizer qualification (Braine-l'Alleud) | Finalized | End of CY2025 |
| Biologics revenue (Dr. Reddy's collaboration) | ~₹100 crore | FY26 |
| New product launches (US) | ~33 launches | FY26 |
| ROW business | Double | 3–5 years |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated revenue | ₹1,424.9 cr, declined YoY but improved from trailing quarter |
| Consolidated EBITDA | ₹347.5 cr, 24% margin, up 100 bps YoY |
| Consolidated net profit | ₹186.5 cr, up 3% YoY; PAT margin 13% |
| Base business (ex-Cenexi) revenue | ₹1,033.2 cr, 12% YoY decline |
| Base business EBITDA margin | 38%, up from 36% in Q4 FY24 |
| Base business gross margin | 61%, up from 56% in Q4 FY24 |
| Consolidated gross margin | 66%, up from 61% in Q4 FY24 |
| US market volume growth (FY25) | +9% including new launches |
| US market price change (FY25) | -5% |
| New launches contribution to total revenue (FY25) | 6% of total revenue |
| New launches gross margin (FY25) | 72% vs company average of 58% |
| ROW market revenue | ₹240.4 cr, 17% of total revenue, 14% YoY decrease |
| India market revenue | ₹52.5 cr, 4% of total revenue |
| R&D expenditure | ₹50.3 cr, 4.9% of base business revenue |
| Cenexi revenue | €43 million, affected by lower production at Fontenay facility |
| Cenexi gross margin | 79%, improved from 77% in Q3 FY25 |
| Profit share and milestone income | ~₹145 cr profit share (14% of revenue), milestone 6% |
| Enoxaparin and Heparin contribution | 16% of total revenue in Q4 FY25 |
| US new product launches in Q4 | 4 new molecules launched |
| Total cash and cash equivalents | ₹2,556.2 cr as of March 31, 2025; net cash ₹2,287 cr after Cenexi debt |
| CAPEX | ₹88.6 cr in Q4 FY25 |
| Cash conversion cycle | 172 days for 12 months ending March 2025, vs 173 days prior year |
| FY26 consolidated revenue growth guidance | Mid-teens growth expected |
| Cenexi positive EBITDA target | Q3 FY26 |
| Cenexi double-digit EBITDA margin target | FY27 |
| Biologics revenue expected in FY26 | ~₹100 cr |
| US expected growth in FY26 | 18%, 12% from products and 6% from CMO projects |